Spots Global Cancer Trial Database for Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

Official Title: A Single-center, Single-arm, Prospective Clinical Study on the Efficacy and Safety of Venetoclax and Azacitidine Combined With HAAG in the Induction Treatment of Intermediate and High-risk Acute Myeloid Leukemia

Study ID: NCT06394011

Conditions

Intermediate Risk Acute Myeloid Leukemia

High Risk Acute Myeloid Leukemia

Interventions

venetoclax, azacitidine and HAAG regimen

Study Description

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of VA combined with HAAG in the induction treatment of newly diagnosed acute myeloid leukemia.

Detailed Description: This is a single-center, single-arm, prospective clinical study in newly diagnosed intermediate and high-risk AML patients. The patients will receive venetoclax, azacitidine combined with HAAG regimen in the induction treatment.